HIV, HCV, and HBsAg (HHH) detection in blood banks before transfusion is important for disease control, timely diagnosis, and prevention of their transmission, as these 3 markers are highly infectious. Chemiluminescence immunoassay CLIA have superior sensitivity, high specificity & rapid turnaround times compared to ELISA or radioimmunoassay. CLIA technology also facilitates accurate detection of analytes at very low concentrations, enhancing its performance in minimising false results and improving diagnostic accuracy. Additionally, its compatibility with automation and high-throughput testing makes chemiluminescence highly stable for regular clinical laboratories and blood screening.
Clinical Significance of Chemiluminescence in HHH range and Interpretation
- CLIA have excellent sensitivity for detecting both low and high concentrations of analytes in HIV, HCV & HBsAg, making it highly suitable for early diagnosis.
- Due to its low detection limits, CLIA can accurately identify very small amounts of analytes, which is important for detecting low-level HBsAg in clinical samples.
- Chemiluminescence technology plays a crucial role in infectious disease diagnosis in Blood banks to ensure safe blood transfusion and patient safety.
- CLIA tests for HIV and HBsAg screening are fourth-generation tests, as they detect both HIV antigens (p24) and antibodies and have better analytical sensitivity for HBsAg, thereby improving detection in early infection.
Interpretation of chemiluminescence results in HHH range:
The result interpretation is based on the sample-to-cutoff ratio (S/CO) in LIA. Since these are sensitive tests, borderline reactive samples should be carefully reanalysed through repeat testing and correlated with clinical symptoms and other diagnostic investigations for highly accurate & clinical interpretation.
Different diagnostic tests for HIV, HCV, and HBsAg (HHH)
Commonly used methods to detect HIV, HCV, and HBsAg in blood banks include electrochemiluminescence (ECLIA), Chemiluminescence Immunoassay (CLIA) & Enzyme-Linked Immunosorbent Assay (ELISA).
The 4th generation HIV chemiluminescence immunoassay, designed for the qualitative detection of antibodies to HIV-1 and HIV-2 and HIV-1 p24 antigen ,HBsAg CLIA for Hepatitis B surface antigen (HBsAg) and HCV CLIA for HCV Antibody detection is primarily used as a screening test for blood donors before transfusion to ensure blood safety.
Conclusion:
In conclusion, CLIA offers significant advantages over traditional ELISA and rapid tests for HIV, HCV & HBsAg screening, especially in terms of sensitivity, speed & automation in high-volume settings. CLIA utilises a luminescent molecule to emit light, providing an absolute measurement that results in superior analytical performance. CLIA also provides a wide linear range, allowing for precise detection of HHH markers compared to the limited absorbance range of ELISA. These methods also elevate workflow efficiency and decrease diagnostic errors, thereby ensuring safe blood transfusion in Blood banks and better patient management in Laboratories.
Explore the Product…
